All In Biotech

Drug Trial Radar · NCT03545191

Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects With Insomnia Disorder

Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Polysomnography Study to Assess the Efficacy and Safety of ACT-541468 in Adult and Elderly Subjects With Insomnia Disorder

Last checked: Nov 19, 2026Latest source record: Mar 25, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 930 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

930

Actual

Start

Jun 4, 2018

Primary completion

Jan 25, 2020

Study completion Feb 25, 2020

Sponsor

Lead sponsor
Idorsia Pharmaceuticals Ltd.Industry
Sponsor type
Industry
First posted
Jun 4, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to assess efficacy and safety of ACT-541468 (daridorexant) in adult and elderly subjects with insomnia disorder. Efficacy will be evaluated on objective and subjective sleep parameters.

Conditions

  • Insomnia Disorder

Interventions

  • Daridorexant 25 mgDrug

    Daridorexant will be administered as tablets, orally, once daily in the evening.

  • Daridorexant 50 mgDrug

    Daridorexant will be administered as tablets, orally, once daily in the evening.

  • PlaceboOther

    Matching placebo will be administered as tablets, orally, once daily in the evening.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Month 1 in Wake After Sleep Onset (WASO) (Sleep Maintenance)Time frame: From baseline to Month 1 (i.e. for up to 1 month)
  2. Change From Baseline to Month 3 in Wake After Sleep Onset (WASO)Time frame: From baseline to Month 3 (i.e. for up to 3 months)
  3. Change From Baseline to Month 1 in Latency to Persistent Sleep (LPS) (Sleep Onset)Time frame: From baseline to Month 1 (i.e. for up to 1 month)
  4. Change From Baseline to Month 3 in Latency to Persistent Sleep (LPS)Time frame: From baseline to Month 3 (i.e. for up to 3 months)

Locations

81 sites in 10 countries. Site status is shown where the registry gives one.

  • Pinnacle Research Group, LLC

    Anniston, Alabama

  • Pulmonary Associates of the Southeast/WCR

    Birmingham, Alabama

  • Preferred Research Partners, Inc

    Little Rock, Arkansas

  • Woodland Research Northwest

    Rogers, Arkansas

  • Marvel Clinical Research

    Huntington Beach, California

  • Long Beach Clinical Trials

    Long Beach, California

  • Artemis Institute for Clinical Research

    San Diego, California

  • PAB Clinical Research

    Brandon, Florida

  • St. Francis Sleep Allergy and Lung Institute

    Clearwater, Florida

  • Innovative Clinical Research, Inc.

    Hialeah, Florida

  • Research Centers of America

    Hollywood, Florida

  • Canvas Clinical Research, LLC

    Lake Worth, Florida

  • BioMed Research Institute

    Miami, Florida

  • Clinical Site Partners, LLC

    Winter Park, Florida

  • LaPorte County Institute for Clinical Research

    Michigan City, Indiana

  • Kentucky Research Group

    Louisville, Kentucky

  • Helene Emsellem, MD

    Chevy Chase, Maryland

  • Infinity Medical Research, Inc.

    North Dartmouth, Massachusetts

  • Barrett Clinic

    La Vista, Nebraska

  • Clinical Research Center of Nevada

    Las Vegas, Nevada

  • Clinilabs NYC

    New York, New York

  • Research Carolina of Huntersville

    Huntersville, North Carolina

  • Coastal Carolina Healthcare

    New Bern, North Carolina

  • CTI Clinical Research Center

    Cincinnati, Ohio

  • Oregon Center for Clinical Investigations,Inc

    Salem, Oregon

  • BTC of Lincoln

    Lincoln, Rhode Island

  • Omega Medical Research

    Warwick, Rhode Island

  • Bogan Sleep Consulting, LLC

    Columbia, South Carolina

  • Coastal Carolina Research Center

    Mt. Pleasant, South Carolina

  • Tri-State Mountain Neurology

    Johnson City, Tennessee

  • Inquest Clinical Research

    Baytown, Texas

  • Sleep Therapy & Research Center

    San Antonio, Texas

  • Aspen Clinical Research

    Orem, Utah

  • Pulmonary Associates of Richmond

    Richmond, Virginia

  • Sleep Disorders Centers of the Mid-Atlantic

    Vienna, Virginia

  • Swedish Medical Center

    Seattle, Washington

  • Respiratory Clinical Trials

    Adelaide, Australia

  • Genesis Sleep Care Queensland

    Auchenflower, Australia

  • Melbourne Sleep Disorders Centre

    East Melbourne, Australia

  • The Woolcock Institute of Medical Research

    Glebe, Australia

Showing 40 of 81 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.